AbbVie reported strong Q1 2026 results with immunology revenue rising 12.4% year-over-year, led by Skyrizi and Rinvoq growth. Despite a 46% net income drop due to a large R&D charge and declines in older drugs like Humira, the company’s pipeline and new drug momentum support long-term growth. Analysts see about 14% upside in the next year, but a $300 share price by 2030 is feasible if key drugs maintain growth and R&D charges normalize. The stock currently trades at a low forward P/E of 17x, making the multi-year target realistic if risks like legacy drug erosion are managed.
Investing in three blue-chip dividend stocks—Altria, AbbVie, and Chevron—each paying dividends quarterly on different schedules, can create a monthly income stream throughout the year. Altria pays in January, April, July, and October with a high yiel...
With inflation expected to remain high, five Dividend Aristocrats—companies with 25+ years of rising dividends—are recommended for investors seeking stable income and growth. These firms, including AbbVie, Chevron, PepsiCo, Procter & Gamble, and Targ...
AbbVie has submitted an application to the European Medicines Agency (EMA) for approval of SKYRIZI (risankizumab) as a subcutaneous induction treatment for adults with moderately to severely active Crohn's disease. This follows positive results from ...
AbbVie continues to demonstrate solid revenue and earnings growth driven by the strong performance of Skyrizi and Rinvoq, which compensate for declines in Humira sales. Recent regulatory approvals and expanded market opportunities support the company...
